Senti Biosciences, Inc. (SNTI)

0.3700 +0.0013 (+0.35%) At close: 04:00PM EDT

Senti Biosciences, Inc.

2 Corporate Drive
First Floor
South San Francisco, CA 94080
United States
650 239 2030
https://www.sentibio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 48

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Timothy K. Lu M.D., Ph.D.	Co-founder, CEO, President & Director	868.57k	N/A	1981
Dr. Deborah A. Knobelman Ph.D.	CFO, Head of Corporate Development & Treasurer	620.88k	N/A	1974
Ms. Susan D. Berland	Senior Financial Executive & Independent Director	57.5k	N/A	1955
Dr. Kanya Rajangam M.D., Ph.D.	Head of Research & Development and Chief Medical Officer	689.99k	N/A	1974
Dr. Wilson Wong Ph.D.	Scientific Co-Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Mr. Mike Rhee	Senior VP of Legal Affairs & Corporate Secretary	N/A	N/A	N/A
Susan Kahlert	Controller	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Corporate governance

Senti Biosciences, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.